623 related articles for article (PubMed ID: 26037043)
61. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
[TBL] [Abstract][Full Text] [Related]
62. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
63. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
64. Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT
Sałat K; Kołaczkowski M; Furgała A; Rojek A; Śniecikowska J; Varney MA; Newman-Tancredi A
Neuropharmacology; 2017 Oct; 125():181-188. PubMed ID: 28751195
[TBL] [Abstract][Full Text] [Related]
65. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
66. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
67. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
[TBL] [Abstract][Full Text] [Related]
68. 5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice.
Ballardin D; Makrini-Maleville L; Seper A; Valjent E; Rebholz H
Neurobiol Dis; 2024 Aug; 198():106559. PubMed ID: 38852753
[TBL] [Abstract][Full Text] [Related]
69. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Muñoz A; Carlsson T; Tronci E; Kirik D; Björklund A; Carta M
Exp Neurol; 2009 Sep; 219(1):298-307. PubMed ID: 19500572
[TBL] [Abstract][Full Text] [Related]
70. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
[TBL] [Abstract][Full Text] [Related]
71. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
[TBL] [Abstract][Full Text] [Related]
72. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Jaunarajs KL; Dupre KB; Steiniger A; Klioueva A; Moore A; Kelly C; Bishop C
Neuroreport; 2009 Sep; 20(14):1265-9. PubMed ID: 19633584
[TBL] [Abstract][Full Text] [Related]
73. NLX-112, a highly selective 5-HT
Depoortère R; Bergman J; Beardsley PM; Desai RI; Paronis CA; Walentiny DM; Varney MA; Newman-Tancredi A
Neuropharmacology; 2022 Jun; 210():109025. PubMed ID: 35276118
[TBL] [Abstract][Full Text] [Related]
74. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
75. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
76. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
77. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
[TBL] [Abstract][Full Text] [Related]
78. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Ferger B
Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
[TBL] [Abstract][Full Text] [Related]
79. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
[TBL] [Abstract][Full Text] [Related]
80. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
